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A carbapenem-resistant S. marcescens isolate was recovered from a patient with an inflammed pacemaker
inplantation pocket from a Cardiac Surgery ward in a Hungarian University Hospital. Phenotypic tests and po-
lymerase chain reaction (PCR) confirmed a very rare gene responsible for production of a carbapenemase (blaVIM-
4), which was further characterized by Sanger-sequencing. The characterization of this S. marcescens strain em-
phasizes the ongoing emergence of novel or rare carbapenemases. Strains expressing a weak carbapenemase like
this strain might go unrecognized by routine diagnostics due to low minimum inhibitory concentrations (MICs)
for the bacterial strains producing such enzymes.1. Introduction
Serratiamarcescens (S.marcescens) is themost commonly isolatedspecies
within the genus, which was discovered by Bizio, an Italian pharmacist in
1819, as the cause of the bloody discolouration on cornmeal mush [1].
Members of this species are ubiquitous in the environment; this opportu-
nisticpathogen is an important causeofhospital-acquired infections (HAIs),
which are often associated with serious outbreaks: different contaminated
medical devices, intravenous fluids and medical solutions are frequent
sources of nosocomial infections [2,3]. S. marcescens is most frequently
isolated from respiratory tract infections, including ventilator-associated
bacterial pneumonia, meningitis and ocular infections [4, 5, 6, 7]. Other
common sources include complicated and uncomplicated skin and soft tis-
sue infections, urinary tract infections (UTIs), as well as bloodstream in-
fections [8, 9]. The main risk factors for Serratia bacteraemia/sepsis are
hospitalization, placement of intravenous, intraperitoneal and urinary
catheters and prior instrumentation of the respiratory tract [9, 10, 11].
S. marcescens infections are a great concern, as this organism is intrinsically
resistant to a large number of antibiotics including ampicillin,. Gajdacs).
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evier Ltd. This is an open access aaminopenicillin/β-lactamase-inhibitor combinations, cefuroxime, nitro-
furantoin and polymixins [12]. Resistance in S. marcescens is conferred by
severalchromosomalandplasmid-mediatedresistancedeterminants,which
facilitate the spread of resistance genes among the different species. During
the last two decades, AmpC cephalosporinase–producing S. marcescens,
Enterobacter cloacae and Citrobacter freundii have emerged as of the most
important causes of HAIs and the prevalence of extended-spectrum β-lac-
tamase (ESBL)-producing enzymes in these organisms is very high globally
[13, 14].
Carbapenem-resistance in S. marcescens is still very rare: the possible
mechanisms include the production of plasmid-encoded (KPC, OXA-48,
IMP, VIM, NDM) or chromosomal (SME) metallo-β-lactamases (MBLs)
or porin-mutations. S. marcescens enzymes (SMEs) are class A carbape-
nemases found on the chromosome, which were first identified in the UK
in 1982; these enzymes (NMC-A, Sme-1 to Sme-3, IMI-1) are very rare
and they are inhibited by clavulanic acid [15]. Class B MBLs (i.e. IMP
[Imipenemase], VIM [Verona Integron-encoded Metallo-β-lactamase]
and NDM [New Delhi metallo-beta-lactamase]) are the most common
(they have been reported worldwide but most frequently from Southeast2020
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can hydrolyze the broadest spectrum of β-lactams (except for aztreonam)
and they can spread via plasmids and integrons of S. marcescens [16].
Only a few reports are available on carbapenem-resistant S. marcescens,
where carbapenem-R was attributed to carbapenemase production.
IMP-like MBL were the first reported transferable carbapenemases in
Gram-negative bacteria [17]; in line with this, IMP-1 was the first
carbapenemase identified as a source of acquired resistance to carbape-
nems in a S. marcescens isolate from a patient with a UTI from Japan in
1991 [18]. Although IMP-like MBL was the earliest transferable carba-
penemases reported in Gram-negative bacteria, which was followed by
VIM types, the Verona-integron encoded metallo-beta lactamases
occured mostly in P. aeruginosa isolations and very rarely in the members
of Enterobacterales [19].
2. Case presentation
A 65-year-old male patient was admitted to the Department of In-
ternal Medicine, Albert Szent-Gy€orgyi Clinical Center for a pacemaker
implantation, due to a Grade III AV-block. According to the Institutional
protocols for implantation procedures, a single-dose cefazoline-prophy-
laxis was administered. The patient was released home one week after
the operation without any complaints, however, two weeks later, the
patient returned to the Clinical Center with complaints of a permanent
bleeding of the surgical wound. The pacemaker pocket was re-opened,
and the pacemaker was subsequently removed. In the pacemaker
pocket, a large amount of gore and gelatinous tissue-debris was found.
The debris was removed and from this material, samples were sent to the
microbiology laboratory for analysis. The pacemaker itself as well as the
leads were ruled out as a source of infection. The pocket was drainaged
by povidone-ioidine and a single dose of vancomycin powder for solution
was dispersed at the site locally. The patient received an empiric therapy
of iv. cefprozil; after the microbiology and susceptibility results were
available, therapy was switched to ceftazidime plus gentamicin for 14-d.
According his anamnestic data, the patient has never received any
carbapenem-therapy earlier in life. After treatment as an inpatient, the
patient surgical site healed and no further complications were noted;
subsequently, the patient was discharged. The environment of the Clin-
ical Ward, the patients and the medical staff were screened in line with
national and international infection control guidelines, however, the
strain could not be found in the hospital environment, and none of the
patients or medical staff was found to be a carrier of the strain. Thus, it
was assumed that the strain was introduced to the Ward by the patient.
3. Materials and methods
Sample processing in our Institute was carried out according to
guidelines for routine clinical bacteriology. The wound samples were
cultured on Columbia blood agar (bioMerieux, Marcy-l’Etoile, France),
chocolate agar (bioMerieux, Marcy-l’Etoile, France) and eosine-
methylene blue agar (bioMerieux, Marcy-l’Etoile, France). The identifi-
cation of the isolate was carried out using the VITEK 2 Compact ID/AST
system, according to the manufacturer's recommendations (bioMerieux,
Marcy-l’Etoile, France).
Antimicrobial susceptibility testing and minimum inhibitory con-
centration (MIC) determination were carried out on Mueller-Hinton agar
plates (bioMerieux, Marcy-l’Etoile, France), using disk diffusion and
gradient tests (Liofilchem, Roseto degli Abruzzi, Italy), respectively, as
recommended by EUCAST Standard Procedures. Colistin susceptibility
testing was performed by broth microdilution method (MERLIN Diag-
nostik, Bornheim-Hersel, Germany). Interpretation of the results was
performed based on EUCAST breakpoints v.9.0.
ESBL-production was investigated by a modified double-disk synergy
test, using ceftazidime (30 μg), cefotaxime (30 μg), cefepime (30 μg) and
aztreonam (30 μg) disks, containing 3-aminophenylboronic acid (APB)
(300 μg) opposite to the amoxicillin/calulanic acid (20 μg/10 μg) disk2[20]. The putative carbapenemase-production were detected phenotyp-
ically by the modified Hodge-test and a phenotypic method utilizing
meropenem, cefepime and ceftazidime disks, either alone or combined
with dipicolinic acid (835 μg). Additionally, confirmation of carbapen-
emase production was performed using a phenotypic inhibition assay
with commercially available diagnostic discs (KPC þ MBL Confirmation
ID Kit; Rosco, Taastrup, Denmark).
The molecular characterization of the strain was performed at the
National Institute of Public Health (Budapest, Hungary). The presence of
different MBL genes (blaVIM, blaIMP, blaSIM, blaGIM, blaSPM, blaNDM) and
class-1 integron was tested by a PCRmethod, using primers and technical
specifications described previously [21, 22, 23, 24, 25, 26]. PCR products
were purified (GFX PCR DNA kit Amersham Biosciences). PCR amplicons
were further characterized by Sanger-sequencing. Sequence analysis and
alignment was performed using Vecton NTI suite 9 (InforMax Inc.).
Resulting nucleotide sequences were compared with sequences obtained
from GenBank (http://www.lahey.org/studies/webt.html). The PCR
mapping of integrons was conducted on the isolate using primers
described previously [27].
4. Results of the laboratory analyses
From the wound samples, a S. marcescens strain was isolated in a high
colony-forming unit (CFU). Based on disk diffusion, the strain was
imipenem-R, ertapenem-R and R to 3rd and 4th generation cephalospo-
rins, while gentamicin-S, ciprofloxacin-S, levofloxacin-S and
meropenem-S. MIC values for the investigated strain are presented in
Table 1. The results of phenotypic tests supposed that the strain did not
produce extended-spectrum β-lactamase enzyme, but produced a met-
allo-β-lactamase.
The molecular investigations revealed that the blaVIM-4 metallo-
β-lactamase gene harbored by this isolate was part of a class-1 integron.
According to the INTEGRALL database (http://integrall.bio.ua.pt), this
integron was designated as In238b. The nucleotide sequence of the
integron was assigned to GenBank under accession number JF905459
(https://www.ncbi.nlm.nih.gov/nuccore/JF905459).
5. Discussion
blaIMP and blaVIM genes are horizontally transferable as they are
inserted into integrons (In) and some of these integrons are located on
conjugative plasmids. Due to this ability to spread, carbapenem-
resistance related to IMP and VIM β-lactamases has become a serious
concern. Until now, several outbreaks of KPC-2 producing S. marcescens
has been published [28, 29], however, reports on outbreaks caused by
VIM-producing S. marcescens are infrequent, and most of them occurred
in ICUs [30, 31, 32]. Nastro et al. published the first nosocomial outbreak
(with three patients affected) caused by VIM16-producing S. marcescens
strains in Argentina in 2013 [31]; neither blaCTX-M nor blaPER genes
(which represented the most prevalent ESBLs in Argentina at the time)
were detected in these isolates. Iovene et al. reported the first docu-
mented nosocomial outbreak of VIM-producing S. marcescens in Europe
in an adult ICU [32], with a fatality rate of 50%. Ghait et al. was first to
report the detection of MBL-producing S. marcescens isolates (including
strains harbouring the blaIMP-4 [42.5%] and blaVIM-2 [37.5%] genes) from
inpatients with bacteremias in Egypt [30]. Perez-Viso et al. investigated a
total of 21 S. marcescens isolates which were displaying a
multidrug-resistant phenotype in a Madrid University Hospital. Nineteen
patients (most of them in the ICU; 89%) were colonized with
VIM-1-producing S. marcescens stains; 17 of these isolates were clustered
into a single clone (>95% similarity) [33].
Carbapenems are usually used as safe last-line treatments for ESBL-
producing Gram-negative bacterial infections; subsequently, acquired
resistance to carbapenems due to carbapenemase production has been
increasingly reported over the last 15 years in Pseudomonas aeruginosa
aeruginosa, Acinetobacter spp., as well as members of the Enterobacterales
Table 1. MIC values of the tested S. marcescens strain.
Antibiotics MIC Interpretation
Imipenem 8 mg/L Resistant
Ertapenem 4 mg/L Resistant
Meropenem 1 mg/L Susceptible
Cefotaxime 128 mg/L Resistant
Ceftazidime 4 mg/L Resistant
Gentamicin 2 mg/L Susceptible
Amikacin 32 mg/L Resistant
Ciprofloxacin 0.5 mg/L Susceptible
Tigecycline 4 mg/L Resistant
Trimethoprim/sulfamethoxazole 4 mg/L Intermediate
Colistin 256 mg/L Resistant
A. Toth et al. Heliyon 6 (2020) e04231order [34, 35]. Some reports highlighted the emergence of
multi-resistant S. marcescens strains: in these studies, S. marcescens iso-
lates produced plasmid-mediated blaIMP-like MBLs or KPC-2 [36,37]. In
contrast, other studies showed MDR S. marcescens strains that remained
sensitive to carbapenems [38]. The strain in our case remained suscep-
tible to gentamicin and fluoroquinolones, therefore still left clinicians
with adequate treatment options. Estimating their incidence, complica-
tions, and attributable mortality associated with multidrug resistant
Serratia is challenging [39]. Our results are consistent with the European
survey on carbapenemase-producing Enterobacterales, which highlighted
the geographical heterogeneity of carbapenemase-producing Enter-
obacterales in the EU and EEA, and the endemic situation in Italy and
Greece, where the incidence of such infections per 100000 patient-days
was the highest of all EU and EEA countries [34, 39, 40, 41]. VIM-type
MBLs occur more often in non-fermenting Gram-negative bacteria,
while among Enterobacterales, these enzymes were detected most
frequently in K. pneumoniae, E. coli or Enterobacter cloacae. According to
the results of the global survey regarding their prevalence in Enter-
obacterales by Matsumura et al., VIM-1 has a global distribution, VIM-2
was present in Mexico and Spain, VIM-4 in Europe (only one
S. marcescens strain from Czech Republic), VIM-5 and -31 in Turkey,
VIM-19, -26, -27 and -33 were limited to Greece, VIM-23 in Mexico and
VIM-29 was present in Saudi Arabia and the UK [42]. The structure of
integron In238b found in this strain was identical with the integron
previously characterized for a VIM-4 bearing P. aeruginosa: this was the
first identified carbapenemase in Hungary in 2002 [43]. In238b was later
found in Aeromonas hydrophila, K. pneumoniae sequence type 11 (ST11)
and Klebsiella oxytoca [27, 44]. The common origin of these integrons
were suspected. In all previously mentioned cases, low-level carbape-
nem-resistance was detected, which may prove to be difficult to detect
using phenotypic methods.
6. Conclusions
To the best of our knowledge, this is the first time that a VIM-type
MBL-producing S. marcescens was isolated from a clinical sample in
Hungary and characterized by sequencing; the isolate was only detected
from the patient, no carrier or environmental source was identified.
Additionally, the patient had no history of ever taking carbapenem an-
tibiotics. The isolation of this VIM-4 producing S. marcescens is yet
another chain in the event of emergence (in a P. aeruginosa strain in
2002) and subsequent dissemination of blaVIM-4 gene in Hungary The
presented results show that the ongoing dissemination of carbapenem-
resistant Enterobacterales is further expanding across healthcare sys-
tems in Europe. This trend highlights the need for enhanced containment
efforts within countries as well as concerted action at a European level.3Declarations
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